Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
Dupixent peak sales ambition raised to more than €13 billion
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Subscribe To Our Newsletter & Stay Updated
